Improving the outcomes of transplantation with bispecific antibodies
Lenalidomide and ibrutinib: do they have a future in treating CLL?
Achieving deep responses in previously treated CLL patients
Exploiting signalling pathways involved in CLL to develop novel therapies
Tsunami of evidence in CLL